Determination of nitrosamine impurities in irbesartan is a critical quality control requirement for pharmaceutical manufacturers, driven by the genotoxic potential of N-nitrosamines and increasingly stringent global regulatory limits. This technical article describes the nitrosamine impurities relevant to irbesartan drug substance and drug product, the ppb-level analytical methods used for their detection and quantification, and the validation and compliance framework based on ICH M7 and major pharmacopoeial standards.
Technical Overview
Irbesartan is an angiotensin II receptor blocker (ARB, sartan class) widely prescribed for the treatment of hypertension and diabetic nephropathy, with a maximum recommended daily dose of 300 mg. Like other tetrazole-containing sartans, its synthetic route may involve sodium azide chemistry, amide solvents such as dimethylformamide (DMF), and secondary or tertiary amine reagents. These conditions can generate nitrosating species, typically from residual nitrite, which react with amines to form N-nitrosamine impurities.
Nitrosamines are classified as probable human carcinogens and belong to the cohort of concern under ICH M7(R2), which mandates the most stringent impurity control strategies. In addition to small-molecule nitrosamines such as NDMA and NDEA, irbesartan itself contains a nitrosatable amine within its azaspiro ring system and can form N-nitroso-irbesartan, a nitrosamine drug-substance-related impurity (NDSRI). Regulatory surveys of marketed sartan products have identified NDSRIs at levels of concern, resulting in voluntary recalls and intensified batch testing requirements.
Control limits are derived from compound-specific acceptable intake (AI) values expressed in ng/day. The permissible concentration in the drug product is calculated as: limit (ppm) = AI (ng/day) ÷ maximum daily dose (mg/day). For irbesartan at 300 mg/day, commonly referenced limits include approximately 0.32 ppm for NDMA (AI 96 ng/day) and approximately 0.09 ppm for NDEA (AI 26.5 ng/day). For N-nitroso-irbesartan, the applicable health-authority AI must be applied, and where a compound-specific value is not established, conservative threshold-based limits (for example, 18 ng/day per the EMA approach for nitrosamines) are frequently adopted. These low limits demand confirmatory analytical methods with quantification capability at single-digit ppb levels.
Testing Samples
Irbesartan Active Pharmaceutical Ingredient (API)
Representative API samples are tested for both small-molecule nitrosamines and N-nitroso-irbesartan. Testing supports batch release, process optimization, solvent recovery control, and risk assessment activities under GMP. Risk-based skip-lot testing may be justified when robust process controls and historical data demonstrate consistent nitrosamine control.
Finished Dosage Forms
Irbesartan tablets (typically 75 mg, 150 mg, and 300 mg strengths) and fixed-dose combination products, such as irbesartan with hydrochlorothiazide, are tested to verify that nitrosamine levels remain below the AI-derived limits. Composited sample preparations of multiple dosage units are commonly used to account for content uniformity, and matrix effects from excipients must be addressed during method development.
Process Intermediates, Raw Materials, and Excipients
Upstream control testing covers key synthetic intermediates, starting materials, recovered solvents, and reagents that may carry amines or nitrite into the process. Excipients and purified water used in formulation are also evaluated for nitrite content, since nitrite contamination in drug product matrices is a well-documented driver of NDSRI formation during manufacturing and storage.
Testing Items
A comprehensive nitrosamine screening panel for irbesartan typically includes the following target analytes, with reporting at or below the applicable specification limits:
- N-nitrosodimethylamine (NDMA)
- N-nitrosodiethylamine (NDEA)
- N-nitrosoethylisopropylamine (NEIPA)
- N-nitrosodiisopropylamine (NDIPA)
- N-nitrosodibutylamine (NDBA)
- N-nitroso-N-methyl-4-aminobutyric acid (NMPA)
- N-nitroso-irbesartan (nitrosamine drug-substance-related impurity, NDSRI)
- Nitrite and nitrate content in excipients and process inputs (supporting risk assessment)
Testing Methods
Because nitrosamine limits are expressed at ppb concentrations, highly selective and sensitive hyphenated mass spectrometry techniques are required. Method selection depends on analyte volatility, matrix complexity, and the regulatory method requirements applicable to the target market.
Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
LC-MS/MS on a triple quadrupole instrument is the primary technique for non-volatile and thermally labile nitrosamines, in particular N-nitroso-irbesartan and NMPA. Reversed-phase separation on C18 or phenyl-hexyl columns with water/acetonitrile or water/methanol mobile phases containing formic acid or ammonium formate is combined with positive-mode electrospray ionization. Multiple reaction monitoring (MRM) employs at least two ion transitions per analyte (one quantifier, one qualifier), and quantification is performed with isotope-labeled internal standards, such as labeled NDMA or NDEA surrogates, to correct for matrix effects and extraction variability. Typical limits of quantification reach 0.005–0.01 ppm (5–10 ppb) relative to the drug substance.
Gas Chromatography–Tandem Mass Spectrometry (GC-MS/MS)
GC-MS/MS with electron ionization and headspace or liquid injection is well suited to volatile small nitrosamines such as NDMA, NDEA, NEIPA, NDIPA, and NDBA. Headspace sampling reduces matrix interference from the irbesartan tablet or API matrix and provides excellent chromatographic resolution of low-molecular-weight nitrosamines.
Liquid Chromatography–High-Resolution Mass Spectrometry (LC-HRMS)
LC-HRMS (QTOF or Orbitrap-based accurate mass screening) is used for investigative workflows, including unknown nitrosamine identification, nitrosatable amine surveys, and confirmation of detected impurities by accurate mass and fragmentation pattern. This supports ICH M7 structural alert evaluations and root-cause investigations.
Sample Preparation
Sample preparation is designed to maximize extraction recovery while preventing artifactual nitrosamine formation during analysis. Typical procedures include extraction with acetonitrile/water or methanol/water mixtures, sonication, centrifugation, and dilute-and-shoot injection for APIs, with solid-phase extraction (SPE) or dispersive cleanup for tablet matrices. Controlled pH, minimized hold times, and the use of nitrite scavengers where scientifically justified prevent false positives arising from in-vial nitrosation.
Method Validation
Methods are validated in accordance with ICH Q2(R2), USP General Chapter 1469 (Procedure for the Measurement of Nitrosamine Impurities), and applicable pharmacopoeial requirements, such as the European Pharmacopoeia general chapter on N-nitrosamines. Key validation elements include:
- Specificity and selectivity with qualifier-to-quantifier ion ratio confirmation
- Linearity across the range from LOQ to at least 150–200% of the specification limit, with correlation coefficient typically not less than 0.99
- Accuracy demonstrated by recovery studies, typically within 80–120% (justifiably wider at trace levels)
- Precision with repeatability and intermediate precision RSD generally not more than 10–15%
- Sensitivity with LOQ signal-to-noise of at least 10 and LOQ set at or below one-tenth of the specification limit
- Solution stability, carryover assessment, robustness, and filter compatibility
Applications
Nitrosamine impurity determination for irbesartan supports the full product lifecycle across the pharmaceutical industry:
- GMP batch release testing and routine quality control of API and finished dosage forms
- Regulatory submission support, including method validation packages for DMF, ANDA, and NDA filings
- Risk assessment and root-cause investigation of nitrosamine formation, including nitrite and amine source evaluation
- Stability studies under long-term, accelerated, and in-use conditions to monitor nitrosamine growth
- Supplier qualification and change management for API sources, excipients, and packaging components
- Post-marketing surveillance and import/export testing to satisfy destination pharmacopoeia requirements
- Independent verification testing at ISO/IEC 17025-accredited third-party laboratories for data neutrality and regulatory acceptance
FAQ
Why do nitrosamine impurities form in irbesartan?
Nitrosamines form when nitrosating agents, most commonly residual nitrite, react with secondary or tertiary amines present in reagents, degraded amide solvents, or the irbesartan molecule itself. The azaspiro secondary amine in irbesartan can undergo intramolecular nitrosation to generate N-nitroso-irbesartan, particularly in the presence of nitrite under acidic processing or granulation conditions.
What regulatory limits apply to nitrosamines in irbesartan products?
Limits are derived from acceptable intake values using the formula: limit (ppm) = AI (ng/day) ÷ maximum daily dose (mg/day). For a 300 mg daily dose of irbesartan, this yields approximately 0.32 ppm for NDMA and 0.09 ppm for NDEA. For N-nitroso-irbesartan, the current AI published by the relevant health authority governs; in its absence, a conservative threshold-based value such as 18 ng/day is commonly applied pending compound-specific assessment.
Which analytical technique is most appropriate?
LC-MS/MS is generally the method of choice because it covers both small nitrosamines and the non-volatile NDSRI, N-nitroso-irbesartan. GC-MS/MS with headspace sampling offers superior performance for volatile nitrosamines such as NDMA and NDEA. Many testing strategies combine both platforms, supplemented by LC-HRMS for unknown screening.
How sensitive do the methods need to be?
Regulatory practice requires the LOQ to be at or below approximately one-tenth of the specification limit. Given sub-ppm limits for irbesartan products, validated methods must reliably quantify nitrosamines at 0.005–0.01 ppm (5–10 ppb), which is achievable with triple quadrupole MRM detection and isotope-dilution quantification.
Can sample preparation generate false positives?
Yes. Acidic extraction conditions with residual nitrite can induce artifactual nitrosamine formation in the vial. Validated methods control pH, limit solution hold times, and where justified employ nitrite scavengers, and they confirm findings with orthogonal chromatography and qualifier ion ratios.
What are typical sample requirements and turnaround times?
A typical study requires several grams of API or an equivalent number of finished dosage units, along with product composition and daily dose information to establish specification limits. Routine quantitative testing at an experienced laboratory is generally completed within five to fifteen business days, with investigative or confirmatory workflows requiring additional time.
